Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free SUPN Stock Alerts

Supernus Pharmaceuticals (SUPN) Competitors

Supernus Pharmaceuticals logo
$49.19 +0.56 (+1.15%)
As of 04:00 PM Eastern
Compare

SUPN vs. CORT, NKTR, PRGO, OMER, and PCRX

Should you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Corcept Therapeutics (CORT), Nektar Therapeutics (NKTR), Perrigo (PRGO), Omeros (OMER), and Pacira BioSciences (PCRX). These companies are all part of the "pharmaceuticals" industry.

How does Supernus Pharmaceuticals compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

In the previous week, Corcept Therapeutics had 11 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 25 mentions for Corcept Therapeutics and 14 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.75 beat Corcept Therapeutics' score of 0.01 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corcept Therapeutics
4 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral
Supernus Pharmaceuticals
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Corcept Therapeutics has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$761.41M7.24$99.65M$0.35146.76
Supernus Pharmaceuticals$718.95M3.97-$38.55M-$0.68N/A

Corcept Therapeutics currently has a consensus price target of $74.67, suggesting a potential upside of 45.36%. Supernus Pharmaceuticals has a consensus price target of $62.17, suggesting a potential upside of 26.38%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Corcept Therapeutics is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corcept Therapeutics
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.50
Supernus Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Corcept Therapeutics has a net margin of 6.14% compared to Supernus Pharmaceuticals' net margin of -5.36%. Supernus Pharmaceuticals' return on equity of 12.26% beat Corcept Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Corcept Therapeutics6.14% 7.40% 5.76%
Supernus Pharmaceuticals -5.36%12.26%9.21%

93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Corcept Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.

Summary

Corcept Therapeutics beats Supernus Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Nektar Therapeutics?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

75.9% of Nektar Therapeutics shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Supernus Pharmaceuticals has a net margin of -5.36% compared to Nektar Therapeutics' net margin of -297.07%. Supernus Pharmaceuticals' return on equity of 12.26% beat Nektar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals-5.36% 12.26% 9.21%
Nektar Therapeutics -297.07%-380.32%-59.82%

Supernus Pharmaceuticals presently has a consensus price target of $62.17, suggesting a potential upside of 26.38%. Nektar Therapeutics has a consensus price target of $140.63, suggesting a potential upside of 67.09%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Nektar Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73

In the previous week, Nektar Therapeutics had 13 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 27 mentions for Nektar Therapeutics and 14 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.75 beat Nektar Therapeutics' score of 0.10 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Supernus Pharmaceuticals
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nektar Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
23 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Supernus Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500.

Supernus Pharmaceuticals has higher revenue and earnings than Nektar Therapeutics. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$718.95M3.97-$38.55M-$0.68N/A
Nektar Therapeutics$55.23M51.41-$164.08M-$10.20N/A

Summary

Supernus Pharmaceuticals and Nektar Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Perrigo?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Supernus Pharmaceuticals presently has a consensus target price of $62.17, suggesting a potential upside of 26.38%. Perrigo has a consensus target price of $19.33, suggesting a potential upside of 66.64%. Given Perrigo's higher possible upside, analysts plainly believe Perrigo is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Perrigo
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

95.9% of Perrigo shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Supernus Pharmaceuticals has a net margin of -5.36% compared to Perrigo's net margin of -33.51%. Supernus Pharmaceuticals' return on equity of 12.26% beat Perrigo's return on equity.

Company Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals-5.36% 12.26% 9.21%
Perrigo -33.51%9.41%3.97%

In the previous week, Perrigo had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 16 mentions for Perrigo and 14 mentions for Supernus Pharmaceuticals. Perrigo's average media sentiment score of 0.75 beat Supernus Pharmaceuticals' score of 0.75 indicating that Perrigo is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Supernus Pharmaceuticals
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Perrigo
3 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Supernus Pharmaceuticals has higher earnings, but lower revenue than Perrigo. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$718.95M3.97-$38.55M-$0.68N/A
Perrigo$4.25B0.38-$1.43B-$10.28N/A

Supernus Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Summary

Supernus Pharmaceuticals beats Perrigo on 10 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Omeros?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Omeros (NASDAQ:OMER) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Supernus Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.66, indicating that its stock price is 166% more volatile than the S&P 500.

Supernus Pharmaceuticals currently has a consensus target price of $62.17, indicating a potential upside of 26.38%. Omeros has a consensus target price of $40.33, indicating a potential upside of 173.08%. Given Omeros' stronger consensus rating and higher probable upside, analysts clearly believe Omeros is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Omeros
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.83

Omeros has lower revenue, but higher earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$718.95M3.97-$38.55M-$0.68N/A
OmerosN/AN/A-$3.35M-$0.50N/A

Omeros has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -5.36%. Supernus Pharmaceuticals' return on equity of 12.26% beat Omeros' return on equity.

Company Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals-5.36% 12.26% 9.21%
Omeros N/A -72.14%59.71%

In the previous week, Supernus Pharmaceuticals had 12 more articles in the media than Omeros. MarketBeat recorded 14 mentions for Supernus Pharmaceuticals and 2 mentions for Omeros. Supernus Pharmaceuticals' average media sentiment score of 0.75 beat Omeros' score of 0.47 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Supernus Pharmaceuticals
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Omeros
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

48.8% of Omeros shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 12.9% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Omeros beats Supernus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Pacira BioSciences?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Supernus Pharmaceuticals presently has a consensus target price of $62.17, suggesting a potential upside of 26.38%. Pacira BioSciences has a consensus target price of $29.40, suggesting a potential upside of 18.60%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Supernus Pharmaceuticals is more favorable than Pacira BioSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Pacira BioSciences
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

Supernus Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500.

99.7% of Pacira BioSciences shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Pacira BioSciences had 7 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 21 mentions for Pacira BioSciences and 14 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.75 beat Pacira BioSciences' score of 0.28 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Supernus Pharmaceuticals
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pacira BioSciences
4 Very Positive mention(s)
3 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pacira BioSciences has a net margin of 0.70% compared to Supernus Pharmaceuticals' net margin of -5.36%. Supernus Pharmaceuticals' return on equity of 12.26% beat Pacira BioSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals-5.36% 12.26% 9.21%
Pacira BioSciences 0.70%10.24%5.47%

Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$718.95M3.97-$38.55M-$0.68N/A
Pacira BioSciences$726.41M1.34$7.03M$0.12206.58

Summary

Supernus Pharmaceuticals beats Pacira BioSciences on 9 of the 16 factors compared between the two stocks.

Get Supernus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SUPN vs. The Competition

Export
MetricSupernus PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.82B$6.00B$6.25B$11.77B
Dividend YieldN/A0.73%2.74%5.26%
P/E Ratio-72.347.9629.2527.07
Price / Sales3.9724.44504.6873.47
Price / Cash12.888.1543.3053.90
Price / Book2.664.099.676.69
Net Income-$38.55M$118.49M$3.55B$332.64M
7 Day Performance1.03%3.14%1.70%2.01%
1 Month Performance-2.56%6.63%5.62%9.19%
1 Year Performance51.87%197.09%34.42%39.59%

Supernus Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SUPN
Supernus Pharmaceuticals
3.5222 of 5 stars		$49.19
+1.2%		$62.17
+26.4%		N/A$2.82B$718.95MN/A580
CORT
Corcept Therapeutics
4.3702 of 5 stars		$47.04
+1.8%		$77.67
+65.1%		N/A$5.06B$761.41M57.42300
NKTR
Nektar Therapeutics
2.8706 of 5 stars		$86.92
+0.2%		$140.63
+61.8%		N/A$2.93B$55.23MN/A220
PRGO
Perrigo
4.6302 of 5 stars		$11.45
-0.3%		$19.33
+68.9%		N/A$1.57B$4.25BN/A8,100
OMER
Omeros
2.1547 of 5 stars		$14.59
-1.0%		$40.33
+176.5%		N/A$1.06BN/AN/A210

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SUPN) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel